Publications
Filters: First Letter Of Title is D [Clear All Filters]
Duration of eptifibatide infusion after percutaneous coronary intervention and outcomes among high-risk patients with non-ST-segment elevation acute coronary syndrome: insights from EARLY ACS." Eur Heart J Acute Cardiovasc Care 2, no. 3 (2013): 246-55.
"Diffusion tensor imaging-based characterization of brain neurodevelopment in primates." Cereb Cortex 23, no. 1 (2013): 36-48.
"DiNAMIC: a method to identify recurrent DNA copy number aberrations in tumors." Bioinformatics 27, no. 5 (2011): 678-85.
"Diseased region detection of longitudinal knee MRI data." Inf Process Med Imaging 23 (2013): 632-43.
"Detection of gene-gene interactions using multistage sparse and low-rank regression." Biometrics 72, no. 1 (2016): 85-94.
"Diseased Region Detection of Longitudinal Knee Magnetic Resonance Imaging Data." IEEE Trans Med Imaging 34, no. 9 (2015): 1914-27.
"Diffusion tensor imaging-based characterization of brain neurodevelopment in primates." Cereb Cortex 23, no. 1 (2013): 36-48.
"Differential damage and repair of DNA-adducts induced by anti-cancer drug cisplatin across mouse organs." Nat Commun 10, no. 1 (2019): 309.
"Dose-finding designs for trials of molecularly targeted agents and immunotherapies." J Biopharm Stat 27, no. 3 (2017): 477-494.
"Differential damage and repair of DNA-adducts induced by anti-cancer drug cisplatin across mouse organs." Nat Commun 10, no. 1 (2019): 309.
"Discussion of "Combining biomarkers to optimize patient treatment recommendation"." Biometrics 70, no. 3 (2014): 707-10.
"Discussion of combining biomarkers to optimize patient treatment recommendations." Biometrics 70, no. 3 (2014): 713-6.
"Development and Validation of a Natural Language Processing Tool to Generate the CONSORT Reporting Checklist for Randomized Clinical Trials." JAMA Netw Open 3, no. 10 (2020): e2014661.
"Discussion of "Combining biomarkers to optimize patient treatment recommendation"." Biometrics 70, no. 3 (2014): 707-10.
"Discussion of combining biomarkers to optimize patient treatment recommendations." Biometrics 70, no. 3 (2014): 713-6.
"Diffusion tensor imaging-based characterization of brain neurodevelopment in primates." Cereb Cortex 23, no. 1 (2013): 36-48.
"Discussion of "Combining biomarkers to optimize patient treatment recommendation"." Biometrics 70, no. 3 (2014): 707-10.
"Discussion of combining biomarkers to optimize patient treatment recommendations." Biometrics 70, no. 3 (2014): 713-6.
"Differences in race, molecular and tumor characteristics among women diagnosed with invasive ductal and lobular breast carcinomas." Cancer Causes Control 30, no. 1 (2019): 31-39.
"Differences in race, molecular and tumor characteristics among women diagnosed with invasive ductal and lobular breast carcinomas." Cancer Causes Control 30, no. 1 (2019): 31-39.
"Differences in race, molecular and tumor characteristics among women diagnosed with invasive ductal and lobular breast carcinomas." Cancer Causes Control 30, no. 1 (2019): 31-39.
"Diseased Region Detection of Longitudinal Knee Magnetic Resonance Imaging Data." IEEE Trans Med Imaging 34, no. 9 (2015): 1914-27.
"Development and Validation of a Natural Language Processing Tool to Generate the CONSORT Reporting Checklist for Randomized Clinical Trials." JAMA Netw Open 3, no. 10 (2020): e2014661.
"Differential damage and repair of DNA-adducts induced by anti-cancer drug cisplatin across mouse organs." Nat Commun 10, no. 1 (2019): 309.
"Dose-finding designs for trials of molecularly targeted agents and immunotherapies." J Biopharm Stat 27, no. 3 (2017): 477-494.
"Data for cancer comparative effectiveness research: past, present, and future potential." Cancer 118, no. 21 (2012): 5186-97.
"DiNAMIC: a method to identify recurrent DNA copy number aberrations in tumors." Bioinformatics 27, no. 5 (2011): 678-85.
"Data for cancer comparative effectiveness research: past, present, and future potential." Cancer 118, no. 21 (2012): 5186-97.
"Detection of gene-gene interactions using multistage sparse and low-rank regression." Biometrics 72, no. 1 (2016): 85-94.
"Differential losses to follow-up that are outcome-dependent can vitiate a clinical trial: Simulation results." J Biopharm Stat 28, no. 4 (2018): 633-644.
"Doubly-robust estimators of treatment-specific survival distributions in observational studies with stratified sampling." Biometrics 69, no. 4 (2013): 830-9.
"Development and Validation of a Natural Language Processing Tool to Generate the CONSORT Reporting Checklist for Randomized Clinical Trials." JAMA Netw Open 3, no. 10 (2020): e2014661.
"Data for cancer comparative effectiveness research: past, present, and future potential." Cancer 118, no. 21 (2012): 5186-97.
"Doubly-robust estimators of treatment-specific survival distributions in observational studies with stratified sampling." Biometrics 69, no. 4 (2013): 830-9.
"Discussion of "Combining biomarkers to optimize patient treatment recommendation"." Biometrics 70, no. 3 (2014): 707-10.
"Discussion of combining biomarkers to optimize patient treatment recommendations." Biometrics 70, no. 3 (2014): 713-6.
"Detection of gene-gene interactions using multistage sparse and low-rank regression." Biometrics 72, no. 1 (2016): 85-94.
"Dynamic treatment regimes, past, present, and future: A conversation with experts." Stat Methods Med Res 26, no. 4 (2017): 1605-1610.
"Diffusion tensor imaging-based characterization of brain neurodevelopment in primates." Cereb Cortex 23, no. 1 (2013): 36-48.
"Differential damage and repair of DNA-adducts induced by anti-cancer drug cisplatin across mouse organs." Nat Commun 10, no. 1 (2019): 309.
"DiNAMIC: a method to identify recurrent DNA copy number aberrations in tumors." Bioinformatics 27, no. 5 (2011): 678-85.
"Differential damage and repair of DNA-adducts induced by anti-cancer drug cisplatin across mouse organs." Nat Commun 10, no. 1 (2019): 309.
"Differential damage and repair of DNA-adducts induced by anti-cancer drug cisplatin across mouse organs." Nat Commun 10, no. 1 (2019): 309.
"DiNAMIC: a method to identify recurrent DNA copy number aberrations in tumors." Bioinformatics 27, no. 5 (2011): 678-85.
"Dose-finding designs for trials of molecularly targeted agents and immunotherapies." J Biopharm Stat 27, no. 3 (2017): 477-494.
"Differential damage and repair of DNA-adducts induced by anti-cancer drug cisplatin across mouse organs." Nat Commun 10, no. 1 (2019): 309.
"Duration of eptifibatide infusion after percutaneous coronary intervention and outcomes among high-risk patients with non-ST-segment elevation acute coronary syndrome: insights from EARLY ACS." Eur Heart J Acute Cardiovasc Care 2, no. 3 (2013): 246-55.
"Duration of eptifibatide infusion after percutaneous coronary intervention and outcomes among high-risk patients with non-ST-segment elevation acute coronary syndrome: insights from EARLY ACS." Eur Heart J Acute Cardiovasc Care 2, no. 3 (2013): 246-55.
"Discussion of "Combining biomarkers to optimize patient treatment recommendation"." Biometrics 70, no. 3 (2014): 707-10.
"Discussion of combining biomarkers to optimize patient treatment recommendations." Biometrics 70, no. 3 (2014): 713-6.
"Diffusion tensor imaging-based characterization of brain neurodevelopment in primates." Cereb Cortex 23, no. 1 (2013): 36-48.
"Diseased Region Detection of Longitudinal Knee Magnetic Resonance Imaging Data." IEEE Trans Med Imaging 34, no. 9 (2015): 1914-27.
"Differences in race, molecular and tumor characteristics among women diagnosed with invasive ductal and lobular breast carcinomas." Cancer Causes Control 30, no. 1 (2019): 31-39.
"Differential damage and repair of DNA-adducts induced by anti-cancer drug cisplatin across mouse organs." Nat Commun 10, no. 1 (2019): 309.
"Differential losses to follow-up that are outcome-dependent can vitiate a clinical trial: Simulation results." J Biopharm Stat 28, no. 4 (2018): 633-644.
"Data for cancer comparative effectiveness research: past, present, and future potential." Cancer 118, no. 21 (2012): 5186-97.
"Data for cancer comparative effectiveness research: past, present, and future potential." Cancer 118, no. 21 (2012): 5186-97.
"Duration of eptifibatide infusion after percutaneous coronary intervention and outcomes among high-risk patients with non-ST-segment elevation acute coronary syndrome: insights from EARLY ACS." Eur Heart J Acute Cardiovasc Care 2, no. 3 (2013): 246-55.
"Detection of gene-gene interactions using multistage sparse and low-rank regression." Biometrics 72, no. 1 (2016): 85-94.
"Dynamic treatment regimes, past, present, and future: A conversation with experts." Stat Methods Med Res 26, no. 4 (2017): 1605-1610.
"Dynamic treatment regimes, past, present, and future: A conversation with experts." Stat Methods Med Res 26, no. 4 (2017): 1605-1610.
"Data for cancer comparative effectiveness research: past, present, and future potential." Cancer 118, no. 21 (2012): 5186-97.
"DiNAMIC: a method to identify recurrent DNA copy number aberrations in tumors." Bioinformatics 27, no. 5 (2011): 678-85.
"Doubly-robust estimators of treatment-specific survival distributions in observational studies with stratified sampling." Biometrics 69, no. 4 (2013): 830-9.
"Duration of eptifibatide infusion after percutaneous coronary intervention and outcomes among high-risk patients with non-ST-segment elevation acute coronary syndrome: insights from EARLY ACS." Eur Heart J Acute Cardiovasc Care 2, no. 3 (2013): 246-55.
"Discussion of "Combining biomarkers to optimize patient treatment recommendation"." Biometrics 70, no. 3 (2014): 707-10.
"Discussion of combining biomarkers to optimize patient treatment recommendations." Biometrics 70, no. 3 (2014): 713-6.
"Diseased region detection of longitudinal knee MRI data." Inf Process Med Imaging 23 (2013): 632-43.
"Diseased Region Detection of Longitudinal Knee Magnetic Resonance Imaging Data." IEEE Trans Med Imaging 34, no. 9 (2015): 1914-27.
"Dose-finding designs for trials of molecularly targeted agents and immunotherapies." J Biopharm Stat 27, no. 3 (2017): 477-494.
"Dynamic treatment regimes, past, present, and future: A conversation with experts." Stat Methods Med Res 26, no. 4 (2017): 1605-1610.
"Differential losses to follow-up that are outcome-dependent can vitiate a clinical trial: Simulation results." J Biopharm Stat 28, no. 4 (2018): 633-644.
"Differences in race, molecular and tumor characteristics among women diagnosed with invasive ductal and lobular breast carcinomas." Cancer Causes Control 30, no. 1 (2019): 31-39.
"Development and Validation of a Natural Language Processing Tool to Generate the CONSORT Reporting Checklist for Randomized Clinical Trials." JAMA Netw Open 3, no. 10 (2020): e2014661.
"Diseased region detection of longitudinal knee MRI data." Inf Process Med Imaging 23 (2013): 632-43.
"Diseased region detection of longitudinal knee MRI data." Inf Process Med Imaging 23 (2013): 632-43.
"Diseased Region Detection of Longitudinal Knee Magnetic Resonance Imaging Data." IEEE Trans Med Imaging 34, no. 9 (2015): 1914-27.
"Diseased region detection of longitudinal knee MRI data." Inf Process Med Imaging 23 (2013): 632-43.
"Differences in race, molecular and tumor characteristics among women diagnosed with invasive ductal and lobular breast carcinomas." Cancer Causes Control 30, no. 1 (2019): 31-39.
"Dose-finding designs for trials of molecularly targeted agents and immunotherapies." J Biopharm Stat 27, no. 3 (2017): 477-494.
"Duration of eptifibatide infusion after percutaneous coronary intervention and outcomes among high-risk patients with non-ST-segment elevation acute coronary syndrome: insights from EARLY ACS." Eur Heart J Acute Cardiovasc Care 2, no. 3 (2013): 246-55.
"Diseased Region Detection of Longitudinal Knee Magnetic Resonance Imaging Data." IEEE Trans Med Imaging 34, no. 9 (2015): 1914-27.
"Diseased region detection of longitudinal knee MRI data." Inf Process Med Imaging 23 (2013): 632-43.
"Diseased Region Detection of Longitudinal Knee Magnetic Resonance Imaging Data." IEEE Trans Med Imaging 34, no. 9 (2015): 1914-27.
"Differential losses to follow-up that are outcome-dependent can vitiate a clinical trial: Simulation results." J Biopharm Stat 28, no. 4 (2018): 633-644.
"Diffusion tensor imaging-based characterization of brain neurodevelopment in primates." Cereb Cortex 23, no. 1 (2013): 36-48.
"Diseased region detection of longitudinal knee MRI data." Inf Process Med Imaging 23 (2013): 632-43.
"Diseased Region Detection of Longitudinal Knee Magnetic Resonance Imaging Data." IEEE Trans Med Imaging 34, no. 9 (2015): 1914-27.
"Duration of eptifibatide infusion after percutaneous coronary intervention and outcomes among high-risk patients with non-ST-segment elevation acute coronary syndrome: insights from EARLY ACS." Eur Heart J Acute Cardiovasc Care 2, no. 3 (2013): 246-55.
"Discussion of "Combining biomarkers to optimize patient treatment recommendation"." Biometrics 70, no. 3 (2014): 707-10.
"Discussion of combining biomarkers to optimize patient treatment recommendations." Biometrics 70, no. 3 (2014): 713-6.
"Diffusion tensor imaging-based characterization of brain neurodevelopment in primates." Cereb Cortex 23, no. 1 (2013): 36-48.
"Dose-finding designs for trials of molecularly targeted agents and immunotherapies." J Biopharm Stat 27, no. 3 (2017): 477-494.
"Dose-finding designs for trials of molecularly targeted agents and immunotherapies." J Biopharm Stat 27, no. 3 (2017): 477-494.
"Differential damage and repair of DNA-adducts induced by anti-cancer drug cisplatin across mouse organs." Nat Commun 10, no. 1 (2019): 309.
"Duration of eptifibatide infusion after percutaneous coronary intervention and outcomes among high-risk patients with non-ST-segment elevation acute coronary syndrome: insights from EARLY ACS." Eur Heart J Acute Cardiovasc Care 2, no. 3 (2013): 246-55.
"Differences in race, molecular and tumor characteristics among women diagnosed with invasive ductal and lobular breast carcinomas." Cancer Causes Control 30, no. 1 (2019): 31-39.
"Detection of gene-gene interactions using multistage sparse and low-rank regression." Biometrics 72, no. 1 (2016): 85-94.
"Dose-finding designs for trials of molecularly targeted agents and immunotherapies." J Biopharm Stat 27, no. 3 (2017): 477-494.
"